top of page

ATXA Therapeutics in Berlin for the EIC Innovators’ Summit 2018

DUBLIN, IRELAND – September 10, 2018 – From 10-11 September 2018, the European Innovation Council (EIC) will host more than 600 top SMEs, researchers, and entrepreneurs from the most relevant innovation funding programmes of the European Union (i.e. SME Instrument, FTI and FET Open) at the EIC Innovators’ Summit in Berlin.

Founder and Chief Scientific Officer, Prof. Therese Kinsella, PhD, MRIA, will be in Berlin representing ATXA Therapeutics, and along with more than 1,000 participants from all over the EU, will have the opportunity to exchange on best practices, pitch our ideas and solutions, attract investors, and engage in new business partnerships.

Already the second summit of its kind, it is the first one to be hosted outside of Brussels. As a major hotspot of innovation, Berlin has been chosen as the first stopover on the summit’s journey across Europe. The event will take place at STATION Berlin. Under the motto “Innovation Kitchen Europe”, expect to find a gourmet menu of engaging keynotes, curated workshops, and enticing pitching sessions with an overall atmosphere of entrepreneurship and creativity.

For more information about EIC Innovators' Summit 2018, please refer to the conference website here.

About ATXA Therapeutics

Headquartered in Dublin, Ireland, ATXA Therapeutics Limited is a spin-out company from University College Dublin whose primary focus is to advance clinical trials and to secure marketing authorization of novel therapies for the treatment of Pulmonary Arterial Hypertension (PAH), serving a previously unmet medical need by offering improved treatment options to the prescribing physician and new hope for the PAH patient. Founded in May 2015, ATXA Therapeutics Limited is the culmination of over 20 years of extensive research and over €15m of grant funding and a proven track record in understanding of the biology and signalling of the human prostanoid receptors in the cardiovascular disease and oncology setting. For more information, please visit

48 views0 comments
bottom of page